Previous Close | 81.98 |
Open | 82.68 |
Bid | 33.01 x 800 |
Ask | 92.98 x 900 |
Day's Range | 81.21 - 83.81 |
52 Week Range | 72.26 - 95.26 |
Volume | |
Avg. Volume | 278,375 |
Market Cap | 4.131B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 32.69 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for HAE
OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF) announces that the Québec Superior Court (the "Court") issued an interim order (the "Interim Order") on October 31, 2023 in connection with the previously announced acquisition by Haemonetics Corporation ("Haemonetics") (NYSE: HAE), a global healthcare company, and 9500-7704 Québec Inc., a wholly-owned subsidiary of Haemonetics ("AcquireCo" and, collectively with Haemonetics, the "Purchaser Parties") of all of the issued and o
Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash tra